Lentiviral Hematopoietic Stem Cell Gene Therapy Benefits Metachromatic Leukodystrophy
Top Cited Papers
- 23 August 2013
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 341 (6148), 1233158-U58
- https://doi.org/10.1126/science.1233158
Abstract
Metachromatic leukodystrophy (MLD) is an inherited lysosomal storage disease caused by arylsulfatase A (ARSA) deficiency. Patients with MLD exhibit progressive motor and cognitive impairment and die within a few years of symptom onset. We used a lentiviral vector to transfer a functional ARSA gene into hematopoietic stem cells (HSCs) from three presymptomatic patients who showed genetic, biochemical, and neurophysiological evidence of late infantile MLD. After reinfusion of the gene-corrected HSCs, the patients showed extensive and stable ARSA gene replacement, which led to high enzyme expression throughout hematopoietic lineages and in cerebrospinal fluid. Analyses of vector integrations revealed no evidence of aberrant clonal behavior. The disease did not manifest or progress in the three patients 7 to 21 months beyond the predicted age of symptom onset. These findings indicate that extensive genetic engineering of human hematopoiesis can be achieved with lentiviral vectors and that this approach may offer therapeutic benefit for MLD patients.Keywords
This publication has 58 references indexed in Scilit:
- Preclinical Safety and Efficacy of Human CD34+ Cells Transduced With Lentiviral Vector for the Treatment of Wiskott-Aldrich SyndromeMolecular Therapy, 2013
- Brain conditioning is instrumental for successful microglia reconstitution following hematopoietic stem cell transplantationProceedings of the National Academy of Sciences of the United States of America, 2012
- Stem-Cell Gene Therapy for the Wiskott–Aldrich SyndromeNew England Journal of Medicine, 2010
- Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemiaNature, 2010
- Gammaretrovirus-mediated correction of SCID-X1 is associated with skewed vector integration site distribution in vivoJCI Insight, 2007
- Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapyJCI Insight, 2007
- Gene therapy of metachromatic leukodystrophy reverses neurological damage and deficits in miceJCI Insight, 2006
- RTCGD: retroviral tagged cancer gene databaseNucleic Acids Research, 2004
- A Serious Adverse Event after Successful Gene Therapy for X-Linked Severe Combined ImmunodeficiencyNew England Journal of Medicine, 2003
- New genes involved in cancer identified by retroviral taggingNature Genetics, 2002